North China Pharmaceutical (600812) released its 2016 annual performance: the company saw a year-on-year growth of 2.28% in operating revenue, realizing ￥8,082 million; and gained a net profit of ￥54 million which decreased by 13.42% on year-on-year basis. Among which, the operating revenue from vitamin and nutritional healthcare products saw a year-on-year decline of 13.54%, realized ￥229 million. The subsidiaries Hebei Welcome Pharmaceutical Co., Ltd. and North China Pharmaceutical Victor Co., Ltd. started to remove and halted the production in 2015 as required by the government, thus the company’s revenue from vitamin decreased greatly; the general pharmaceutical factory started to remove and halted the partial production as required by the government in 2016, giving rise to the sharp decrease in the revenue from chemical raw medicine and nutritional healthcare products.